More on CRSP
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $58.33 |
|
|||
| Open | $58.73 | ||||
| 52 Wk High | $18.88 | ||||
| 52 Wk Low | $13.75 | ||||
| Day High | $60.72 | ||||
| Day Low | $57.64 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 2,083,466 | ||||
- Form 144 CRISPR Therapeutics AG Filed by: KASINGER JAMES R.
- Form 4 CRISPR Therapeutics AG For: Sep 17 Filed by: Behbahani Ali
- Form 4 CRISPR Therapeutics AG For: Aug 06 Filed by: Behbahani Ali
- Form 144 CRISPR Therapeutics AG Filed by: Behbahani Ali
- Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'
- H.C. Wainwright Reiterates Buy Rating on CRISPR Therapeutics (CRSP)
- CRISPR Therapeutics (CRSP) Reiterated at Market Outperform by Citizens on CTX310 Data
- CRISPR Therapeutics reports one-year CTX310 lipid-lowering data
- CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
- CRISPR Therapeutics (CRSP) Reiterated at Market Outperform by Citizens
Entities mentioned with CRSP
- FDA | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- Goldman Sachs | View Related Stories »
- 13G | View Related Stories »
- Show More...
